Maddi Hebebrand, MC, Associate Editor

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

The oral degrader produced biomarker reductions consistent with or superior to dupilumab, according to data presented at EADV 2025.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

Presented at EADV Congress 2025, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

Data presented at EADV 2025 on the ROCKET-SHUTTLE trial demonstrate that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

Balinatunfib was generally well tolerated, with common adverse events such as nausea and arthralgia also observed in placebo groups, according to data from EADV 2025.

Almirall's POSITIVE study, presented at EADV 2025, prioritizes patient well-being, showcasing the holistic impact of advanced treatments.

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

At the 2025 EADV Congress in Paris, phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.

The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

By blocking 2 key inflammation signals, research presented at EADV found bimekizumab may help keep both skin and joints healthier over time.

At EADV, research showed benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

A new hybrid model combining deep learning with clinical data achieved high accuracy in predicting sentinel lymph node metastasis in melanoma.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Dermatologists and hairstylists unite to address scalp health, cultural practices, and patient care at the Science of Skin & Scalp Studio event.

New guidelines enhance understanding and treatment of genital psoriasis, addressing its psychological impact and improving patient-provider communication.

Upadacitinib maintained high EASI and itch response rates through nearly 3 years of treatment.

Phase 3 trials demonstrated that icotrokinra met all primary and co-primary endpoints, including PASI 90 and IGA 0/1 responses.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

Discover the benefits of RetaXome therapy for sensitive skin and its potential in skin care routines.

The new product expands Obagi Medical’s portfolio beyond skin care into injectables.

Forty percent of participants achieved at least a 75% reduction in facial vitiligo scores.

Greater awareness of UV risks and stricter sun protection have contributed to declining invasive melanoma rates.

Novel formulations like retinal-infused exosomes represent an evolution rather than a replacement of retinoid therapy.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.